Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant
Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy
after R0 or R1 resection in patients with pancreatic ductal adenocarcinoma.